Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific
driver alterations, many of which are underrepresented in the current classification schemas …

The genomic and clinical information used to develop and implement therapeutic
approaches for acute myelogenous leukemia (AML) originated primarily from adult patients …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using
whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL …

Contemporary treatment of pediatric acute myeloid leukemia (AML) requires the assignment
of patients to specific risk groups. To explore whether expression profiling of leukemic blasts …

Studies have revealed key genomic aberrations in pediatric acute myeloid leukemia (AML)
based on Western populations. It is unknown to what extent the current genomic findings …

Recent advances in the genetic understanding of acute myeloid leukemia (AML) have
improved clinical outcomes in pediatric patients. However,∼ 40% of patients with pediatric …

This review aims to provide an overview of the current knowledge of the genetic lesions
driving pediatric acute myeloid leukemia (AML), emerging biological concepts, and …

Abstract Purpose of Review Acute myeloid leukemia (AML) in children remains a
challenging disease to cure with suboptimal outcomes particularly when compared to the …

Despite major treatment improvements over the past decades, pediatric acute myeloid
leukemia (AML) is still a life-threatening malignancy with relapse rates up to 30% and …

Acute myeloid leukemia (AML) is a hematopoietic malignancy that is the culmination of
genetic and epigenetic alterations in the hematopoietic stem/progenitor cells, leading to …